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BACKGROUND: Ewing sarcoma (ES) is driven by fusion of the Ewing sarcoma breakpoint region 1 gene (EWSR1) with an E26
transformation-specific (ETS) transcription factor (EWS-ETS), most often the Friend leukemia integration 1 transcription factor (FLI1).
Neuropeptide Y (NPY) is an EWS-FLI1 transcriptional target; it is highly expressed in ES and exerts opposing effects, ranging from ES
cell death to angiogenesis and cancer stem cell propagation. The functions of NPY are regulated by dipeptidyl peptidase IV (DPPIV),
a hypoxia-inducible enzyme that cleaves the peptide and activates its growth-promoting actions. The objective of this study was to
determine the clinically relevant functions of NPY by identifying the associations between patients’ ES phenotype and their NPY con-
centrations and DPP activity. METHODS: NPY concentrations and DPP activity were measured in serum samples from 223 patients
with localized ES and 9 patients with metastatic ES provided by the Children’s Oncology Group. RESULTS: Serum NPY levels were
elevated in ES patients compared with the levels in a healthy control group and an osteosarcoma patient population, and the ele-
vated levels were independent of EWS-ETS translocation type. Significantly higher NPY concentrations were detected in patients
with ES who had tumors of pelvic and bone origin. A similar trend was observed in patients with metastatic ES. There was no effect
of NPY on survival in patients with localized ES. DPP activity in sera from patients with ES did not differ significantly from that in
healthy controls and patients with osteosarcoma. However, high DPP levels were associated with improved survival. CONCLUSIONS:
Systemic NPY levels are elevated in patients with ES, and these high levels are associated with unfavorable disease features. DPPIV in
serum samples from patients with ES is derived from nontumor sources, and its high activity is correlated with improved survival.
Cancer 2015;121:697-707. VC 2014 American Cancer Society.
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INTRODUCTION
Ewing sarcoma (ES) is an aggressive malignancy of children and adolescents arising in bones or soft tissues. The presence
of metastases is the most powerful adverse prognostic factor in ES, with a 5-year event-free survival (EFS) rate of 72% and
a 3-year EFS rate of 27% for patients with localized and metastatic disease, respectively.1,2 Although pulmonary metasta-
ses are the most common, the prognosis is worse for patients who have secondary bone tumors, particularly when both
bone and lung metastases are present (EFS rate, 8%-14%).1 Among patients who have localized disease, pelvic tumors
carry a worse prognosis.3
Malignant transformation of ES is driven by chromosomal translocations resulting in fusion of the Ewing sarcoma
breakpoint region 1 (EWSR1) gene with an E26 transformation-specific (ETS) transcription factor (EWS-ETS).4 The
most common fusion types include EWS–Friend leukemia integration 1 transcription factor (EWS-FLI1) transcripts,
which vary in their fusion sites, and EWS–v-ets avian erythroblastosis virus E26 oncogene homolog (EWS-ERG).
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However, recent studies have identified other ETS pro-
teins that fuse with EWS as well as novel translocations
associated with ES and ES-related tumors that do not con-
tain the EWSR1 gene.5
Microarray analyses have identified multiple tran-
scriptional targets of the EWS-FLI1 protein that are up-
regulated in ES, including neuropeptide Y (NPY) and its
receptors: NPY receptor type 1 and type 5 (Y1R and
Y5R).6 NPY is a 36-amino-acid sympathetic neurotrans-
mitter that regulates cell proliferation and differentiation
and acts as an angiogenic factor.7-9 Moreover, NPY con-
trols bone homeostasis by blocking osteoblast differentia-
tion.10 There is also growing evidence of NPY’s role in the
regulation of tumor growth through both its angiogenic
activity and its direct effects on tumor cells.8,11-13 It is
noteworthy that, in tumors of sympathetic origin, such as
neuroblastoma and pheochromocytoma, NPY release
manifested by its elevated systemic levels in patients has
been associated with an aggressive phenotype of the dis-
ease.14-17 No such correlations have bene observed for
intratumoral NPYmessenger RNA (mRNA) levels.
The role of NPY in ES remains unclear. Initial studies
from our laboratory indicated that NPY could stimulate cell
death through the activation of both Y1R and Y5R.11,12
Consequently, exogenous NPY inhibited ES cell survival in
vitro and the growth of primary tumors in an ES xenograft
model.11,12 However, we have also demonstrated that, in
the hypoxic tumor microenvironment, the actions of en-
dogenous NPY shift to Y2R/Y5R-driven effects that are
known to promote tumor dissemination, such as ES cancer
stem cell proliferation and migration, as well as angiogene-
sis.13 This hypoxia-induced switch in NPY actions is medi-
ated by increased Y2R and Y5R expression and also by the
stimulation of dipeptidyl peptidase IV (DPPIV), a mem-
brane protease that converts full-length NPY1-36 to the
selective Y2R/Y5R agonist, NPY3-36.
12,13 Thus, DPPIV is a
key regulator of NPY actions in ES, shifting its activity from
Y1R/Y5R-mediated growth inhibition to Y2R/Y5R-medi-
ated, potentially prometastatic effects. However, the prote-
ase also modifies a variety of other peptides and augments
the cellular immune response.18,19
High endogenous NPY expression in tumors often
leads to its elevated systemic levels.14-17 We have also dem-
onstrated that high levels of DPPIV in ES xenografts result
in its elevated activity in plasma.12 Therefore, the objective
of the current study was to assess NPY levels and DPPIV
activity in sera from patients with ES and determine
whether the pattern of their release correlates with a specific
disease phenotype, providing insight into clinically relevant
functions of the peptide. We have demonstrated for the
first time that systemic NPY levels are highly elevated in
patients who have ES with unfavorable disease features.
Thus, our data corroborate results from previous experi-
mental studies demonstrating a hypoxia-induced, prometa-
static effect of NPY.13 In contrast, DPPIV detectable in
patients’ sera is derived from nontumor sources, and its
high activity is correlated with better EFS.
MATERIALS AND METHODS
Human Samples
In total, 232 serum samples from patients with ES and 21
serum samples from patients with osteosarcoma were
received from the Children’s Oncology Group (COG);
31 serum samples from healthy volunteer children, ages 6
to 18 years, were collected at the Georgetown University
Clinical Research Unit; and human tissue sections from
17 archival, paraffin-embedded ES samples were collected
frommultiple institutions in Poland by 1 of the coauthors
(E.I.-S.) in compliance with institutional ethical regula-
tions. Use of these samples was approved by the George-
town University Institutional Review Board.
Cell Culture
Human ES cell lines were obtained and cultured as previ-
ously reported.12
ES Xenografts
SK-ES1 or TC71 cells were injected orthotopically into
gastrocnemius muscles of severe combined-immunodefi-
ciency/beige (SCID/bg) mice.13 Once tumors reached 1
cm3 in size, the primary tumors were excised, and the tis-
sues were collected for analyses.
Real-Time Reverse Transcriptase-Polymerase
Chain Reaction
RNA was isolated using the High Pure RNA Isolation Kit
(Roche Applied Science, Indianapolis, Ind). Complemen-
tary DNA was synthesized using the iScript cDNA Synthe-
sis Kit (Bio-Rad Laboratories, Hercules, Calif) and was
amplified using the ICycler iQ Detection System (Bio-Rad
Laboratories), TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, Calif), and predesigned
primers and fluorescein-labeled probes (Applied Biosys-
tems). The results were calculated using the comparative
Ct method with b-actin as a reference gene.
Tumor Translocations and Gene Expression Data
Translocation and gene expression profiling data for pri-
mary ES tumor samples were provided by the COG.
Fusion type was known for 50 of the evaluated patients as
determined from archived tumor specimens.4 Gene
Original Article
698 Cancer March 1, 2015
expression profiling of 56 archived COG tumor samples
was performed using Affymetrix Human Exon arrays
(Affymetrix, Santa Clara, Calif), and normalization and
transcript summarization of data were achieved using Par-
tek Genomics Suites software (Partek Inc., St. Louis, Mo).
NPY Enzyme-Linked Immunosorbent Assay
Conditioned media were collected from ES cells after 24
hours in culture, and the cells were trypsinized, counted,
and lysed in enzyme-linked immunosorbent assay (ELISA)
assay buffer. NPY concentrations in the cell extracts and cul-
ture media were determined using the Neuropeptide Y
Enzyme Immunoassay Kit (Bachem Peninsula Laboratories,
San Carlos, Calif) and were normalized per milligram of
protein or cell number, respectively. Patient serum samples
were extracted using C18 Sep-columns (Bachem Peninsula
Laboratories), and NPY was measured using an ELISA as
described above. For samples that reached the upper limit of
detection (1.267 ng/mL) in the initial ELISA test and had
sufficient volume, a second assay with a higher dilution was
performed. For volume-limited samples, the upper limit of
detection from the first ELISA test was used. Subsequent sta-
tistical analyses relied on categorized NPY data.
Dipeptidyl Peptidase Activity
Dipeptidyl peptidase (DPP) activity in human serum was
measured colorimetrically at 405 nm, using 1 mM p-
nitroanilide (pNA)-conjugated Gly-Pro dipeptide sub-
strate (Sigma Chemical Company, St. Louis, Mo), as pre-
viously described.12
Immunohistochemistry
Immunostaining of ES xenografts and human tumors was
performed on formalin-fixed, paraffin-embedded tissue
samples using rabbit polyclonal anti-NPY antibody
(Sigma Chemical Company).
Statistical Analyses
Statistical analyses were performed using SigmaStat
(Systat Software, San Jose, Calif), GraphPad (GraphPad
Software, La Jolla, Calif), and SPSS (IBM Corporation,
Armonk, NY) software. For systemic NPY levels and DPP
activity, measurements were divided into 4 rank groups or
were analyzed as continuous variables. The comparisons
were performed using the Kruskal-Wallis test, the Fisher
exact test, the log-rank test, or a Cox proportional hazards
model, as appropriate. For the Cox model, a stepwise
variable-selection procedure was used, starting with sex,
age at enrollment, primary site, randomized treatment
assignment, rank group for NPY, and DPP as continuous
variables. General NPY-immunoreactivity and DPP
activity were compared using a 1-way analysis of variance
and post hoc Bonferroni correction. The comparison of
gene expression levels was performed using a t test.
RESULTS
Systemic NPY Levels are Elevated in Patients
With ES
We previously demonstrated that ES cells expressed high
levels of NPY. To determine whether this high NPY
expression in tumors results in its secretion into the circu-
lation, we measured NPY concentrations in sera from 232
patients with ES, including 223 patients with localized dis-
ease and 9 patients with metastatic disease. Table 1 sum-
marizes the demographic characteristics of these patients.
Patients with osteosarcoma (n5 21) and healthy children
(ages 6-18 years; n5 31) served as reference populations.
NPY concentrations in sera from patients who had
localized ES (mean, 0.940 ng/mL) and metastatic ES
(mean, 1.212 ng/mL) were significantly higher compared
with NPY concentrations in healthy controls (mean,
0.517 ng/mL), suggesting release of the peptide from ES
tumors (Fig. 1A). Patients who had metastatic ES tended
to have higher serum NPY levels compared with those
TABLE 1. Demographic Characteristics of the
Ewing Sarcoma Patient Population Included in the
Study on Serum Neuropeptide Y Levels
Clinical Feature No. of Patients (%)
Sex
Female 94 (42.2)
Male 129 (57.8)
Age at enrollment
<18 196 (87.9)
18 27 (12.1)
Race
Black 2 (0.9)
White 198 (88.8)
Other 9 (4)
Unknown 14 (6.3)
Ethnicity
Hispanic 18 (8.1)
Non-Hispanic 198 (88.8)
Unknown 7 (3.1)
Primary tumor site
Nonpelvic 185 (83)
Pelvic 38 (17)
Randomized treatment assignment
Standard 113 (50.7)
Intensive 110 (49.3)
First event in EFS analysis
No event 156 (69.3)
Relapse 59 (26.5)
Second malignant neoplasm 5 (2.2)
Death 3 (1.4)
Follow-up for patients with “no event”
Median [range] 4.9 [1.8-7.7]
Abbreviations: EFS, event-free survival.
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who had localized ES (P5 .18). However, because of the
limited sample size, no definitive conclusion could be
made. No increased serum NPY levels were observed in
the patients with osteosarcoma (mean, 0.492 ng/mL).
Serum NPY Levels in ES Patients Are Highly
Variable
Despite the overall elevated NPY levels in patients
with ES, the NPY concentrations were highly variable
within the ES population (Fig. 1B). Although 50% of
patients with localized ES had NPY concentrations
greater than the highest control value, the remaining
patients were at the level of healthy controls. Variabili-
ty in systemic NPY concentrations corresponded to a
heterogeneous pattern of NPY immunostaining in
human ES tissues (Fig. 1C). Eleven of 17 tested tissue
samples (65%) exhibited prevalent intracellular stain-
ing; whereas, in 6 samples (35%), the staining was
observed in both cytoplasm and extracellular spaces,
suggesting increased release of NPY.
Figure 1. Ewing sarcoma (ES) tumors secrete various levels of neuropeptide Y (NPY) to the circulation. (A) NPY immunoreactiv-
ity (NPY-ir) was measured by using an enzyme-linked immunosorbent assay in sera from healthy children (ages 6-18 years),
patients with localized ES and metastatic ES, and patients with osteosarcoma. (B) Variability in serum NPY concentrations among
patients with ES (localized and metastatic patients combined) is illustrated. (C) Representative images of human ES tissues
exhibiting different patterns of NPY immunostaining, including accumulation in tumor cell cytoplasm or in extracellular spaces.
Red arrows indicate tumor cells with evident cytoplasmic NPY accumulation, and yellow arrows indicate NPY immunoreactivity in
extracellular spaces.
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ES Cells Vary in NPY Release
The variability in NPY systemic levels and immunostain-
ing patterns suggested differential NPY secretion from ES
tumors. To test this, we compared NPY expression and
release in a panel of ES cell lines. All tested cells had de-
tectable levels of NPY mRNA and intracellular NPY pro-
tein (Fig. 2A,B); however, the cell lines varied in their
release of the peptide: NPY was detectable in conditioned
media from 5 of 9 cell lines (Fig. 2C), and its concentra-
tions were positively correlated with mRNA levels (Fig.
2D). No significant correlation was observed between
NPYmRNA and its intracellular levels.
To determine whether the differences in NPY secre-
tion observed in ES cell lines are maintained in vivo, ES
xenograft tissues derived from 2 cell lines that varied in
NPY release (TC71 and SK-ES1 cells) were immuno-
stained for NPY. In TC71 xenografts, NPY accumulated
mainly in the cytoplasm of tumor cells; whereas, in SK-
ES1 xenografts, NPY immunoreactivity was also detected
in extracellular spaces, suggesting its secretion (Fig. 2E).
This observation was in agreement with high concentra-
tions of the peptide in SK-ES1-conditioned media but
not in TC71-conditioned media (Fig. 2C). These results
corroborated our data in human ES tissues, confirming
variability in the release of NPY from ES tumors.
NPY Levels Are Increased in ES Patients With
Various Translocation Types
Having determined the variability in systemic NPY levels
among patients with ES, we sought to identify which dis-
ease phenotype was associated with elevated peptide levels.
Because NPY is a transcriptional target of EWS-FLI1, we
tested whether its release depends on the fusion type. Se-
rum NPY levels were compared in a cohort of 50 patients
who had known translocation status. All groups of patients
with various EWS-FLI1 translocation types and EWS-
ERG fusion had significantly elevated NPY levels com-
pared with healthy controls (Fig. 3). NPY concentrations
were particularly high in patients who were negative for
EWS-FLI1 and EWS-ERG, although the limited number
of samples precluded a reliable group comparison.
NPY Release Is Elevated in Pelvic ES
Because fusion type did not have an effect on NPY release,
we correlated serum concentrations of the peptide with the
patients’ clinical characteristics (Table 1). No significant
associations between sex, age, or randomized treatment
assignment and NPY levels were observed. However, NPY
was significantly elevated in patients who had
pelvic tumors compared with those who had nonpelvic ES
(Table 2). In total, 55.3% of patients with pelvic primary
tumor sites had NPY levels above the 75th percentile, and
only 18.4% had levels below the median (P 5 1.966 3
1025), indicating increased NPY release from these
tumors.
NPY System Expression Is Increased in Bone ES
Aside from pelvic localization, bone origin of the primary
tumor was also associated with increased NPY release
(Fig. 4A). The comparison was performed in a subset of
66 patients who had known tumor localization. The dif-
ference between bone and extraosseous tumors achieved
statistical significance within subsets of patients who had
pelvic and axial tumors but not in those who had ES local-
ized in the extremities. To determine whether these differ-
ences were correlated with the levels ofNPY transcription,
we interrogated gene expression microarray data from 56
human ES tumors (Fig. 4B). mRNA levels of NPY system
elements were moderately but consistently up-regulated
in bone tumors compared with extraosseous tumors. The
differences in mRNA levels achieved statistical signifi-
cance for DPPIV and Y2R (P 5 .003 and P 5 .046,
respectively), whereas the difference was on the border of
significance for NPY (P5 .052).
Serum NPY Levels Had No Effect on Survival
Among Patients with Localized ES
Patients with localized ES were grouped based on serum
NPY levels into 4 approximately equally sized groups. On
the basis of analyses performed using these quartiles, se-
rum concentrations of NPY did not have an effect on
patient survival (Fig. 5). Because of the small sample size,
patients with metastatic ES were not included in this
analysis.
Tumor DPPIV Does Not Affect Systemic DPP
Activity in Sera From Patients With ES
Because DPPIV regulates NPY actions and its plasma lev-
els are elevated in mice bearing DPPIV-rich ES xeno-
grafts, we tested DPP activity in sera from 179 patients
with ES who were part of the cohort that we used to mea-
sure NPY. DPP activity in patients with ES did not differ
significantly from the activity in our healthy control and
osteosarcoma populations (Fig. 6A). These data indicate
that the enzyme activity measured in these sera is derived
from nontumor sources.
High Systemic DPP Activity Is a Strong
Predictor of Better EFS in Patients With
Localized ES
In contrast to NPY levels, DPP activity had a significant
effect on EFS among patients with localized ES. The
NPY in Patients With Ewing Sarcoma/Tilan et al
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log-rank test for the effect on EFS of DPP activity levels
categorized into quartiles had a P value of .0067, and the
stepwise variable selection in the Cox proportional
hazards model produced a model in which only the DPP
level was statistically significant, with an estimated hazard
ratio of 0.7546 per 0.1 change in DPP activity (Wald
Figure 2. Ewing sarcoma (ES) cells constitutively express neuropeptide Y (NPY) but vary in its release. (A) NPY messenger RNA
(mRNA) levels were measured in a panel of ES cell lines using real-time reverse transcriptase-polymerase chain reaction analysis.
(B) NPY intracellular content was determined in cell extracts from ES cells using an enzyme-linked immunosorbent assay (ELISA).
(C) Concentrations of NPY in conditioned media from ES cells were measured using an ELISA. (D) A positive correlation was
observed between intracellular NPY mRNA and its concentrations in the corresponding conditioned media. (E) NPY immuno-
staining was performed in orthotopic xenograft tissues derived from 2 ES cell lines (TC71 and SK-ES1) that varied in NPY expres-
sion. Red arrows indicate tumor cells with cytoplasmic NPY accumulation, and yellow arrows indicate NPY immunoreactivity
(NPY-ir) in extracellular spaces.
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95% confidence interval, 0.6626-0.8595; P 5 2.216 3
1025) (Fig. 6B). The effect on overall survival was less
pronounced; the log-rank test for the effect on survival of
DPP activity levels categorized into quartiles had a P value
of .1154, and the stepwise selection process in the Cox
model similarly identified only the DPP level as statisti-
cally significant, with an estimated hazard ratio of 0.8227
per 0.1 change in DPP activity (Wald 95% confidence
interval, 0.6921-0.9779; P5 .0269) (Fig. 6C).
DISCUSSION
NPY, as 1 of the EWS-FLI1 target genes, is highly
expressed in ES. In these tumors, the peptide exerts several
opposing effects, such as Y1R/Y5R-mediated cell death,
Y2R/Y5R-dependent angiogenesis, and cancer stem cell
proliferation and migration.11-13 NPY functions are regu-
lated by DPPIV and by a hypoxic tumor environment,
both of which favor its Y2R/Y5R-driven actions.13 Such
complex activities of NPY raise a question regarding
which functions of the peptide affect disease phenotype
and the survival of patients with ES. To address this issue,
we sought to identify the clinical features of ES associated
with elevated NPY release and DPP activity.
The average serum NPY concentration was signifi-
cantly elevated in ES patients compared with healthy con-
trols. No such increase in NPY levels was observed in
patients with osteosarcoma, a tumor that affects a patient
population comparable to patients with ES, indicating
that NPY release is a characteristic of ES. This observation
is consistent with EWS-FLI1–driven expression of NPY.6
The finding that NPY levels were elevated in patients who
had ES with various types of EWS-FLI1 rearrangements
and EWS-ERG fusion implicates NPY as a universal
EWS-ETS target.
Despite the overall elevated NPY levels in patients
with ES, its serum concentrations varied greatly: 50% of
patients who had localized disease had normal serum NPY
levels. Our analysis of ES cell lines revealed significant dif-
ferences in peptide secretion, suggesting that heterogeneous
NPY release can underlie the variability in its systemic con-
centrations among patients with ES. This was further con-
firmed by extracellular NPY immunostaining observed
both in ES xenografts derived from cell lines that release
NPY and in some human ES tissues. Because NPY acts
through cell membrane receptors, the ability of ES cells to
secrete the peptide is an important mechanism regulating
its actions. In ES cell lines, we observed a strong correlation
between NPY mRNA levels and NPY concentrations in
conditioned media. However, no such trend was observed
Figure 3. Serum neuropeptide Y (NPY) levels are elevated in
patients with Ewing sarcoma (ES) independent of the Ewing sar-
coma breakpoint region 1 (EWSR1) (EWS)-E26 transformation-
specific (ETS) transcription factor (EWS-ETS) translocation type.
NPY serum concentrations were compared between healthy
controls (children ages 6-18 years) and patients who had ES with
various types of EWS-ETS translocations. The study was performed
in a cohort of 50 patients who were tested for the presence of the
EWS–Friend leukemia integration 1 transcription factor (EWS-FLI1)
fusion and theEWS–v-ets avian erythroblastosis virus E26 oncogene
homolog (EWS-ERG) fusion. Two of the patients were negative
(NEG) for both types of translocations.
TABLE 2. Neuropeptide Y Concentrations in Sera From Ewing Sarcoma Patients With Pelvic and Nonpelvic
Tumors
No. of Patients (%)
NPY Levels by Percentile
Primary Tumor Site <25th 25th-50th 50th-75th >75th Total P
Nonpelvic 51 (27.6) 53 (28.6) 46 (24.9) 35 (18.9) 185 (100)
Pelvic 4 (10.5) 3 (7.9) 10 (26.3) 21 (55.3) 38 (100) 1.966 3 1025
Abbreviations: NPY, neuropeptide Y.
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in the small population (n 5 6) of patients with ES who
had matching data on NPY mRNA and serum levels (data
not shown). Thus, NPY serum concentrations in patients
may be further modified by tumor mass or by factors that
promote its release in the tumor microenvironment.
One of the stromal factors known for regulating
NPY synthesis and release is brain-derived neurotrophic
factor (BDNF).20 High levels of BDNF are present in the
bone environment, which is in line with elevated expres-
sion and secretion of NPY from bone ES, at least in the
pelvic and axial locations.21 This observation suggests the
potential involvement of NPY in ES bone invasion and is
in agreement with the role of the peptide in regulating
bone homeostasis. It has been demonstrated that NPY
inhibits osteoblast differentiation, which impairs osteo-
genesis and decreases bone density.10 Although bone
lesions in ES are mainly osteolytic, blocking osteogenesis
in pediatric and adolescent patients who have ongoing
bone formation may shift bone homeostasis toward oste-
olysis and promote bone degradation. A similar phenom-
enon has been observed in neuroblastoma, another
pediatric tumor with frequent bone metastases.22
Aside from bone ES, elevated NPY serum concentra-
tions also were observed in patients with pelvic tumors,
which carry a worse prognosis.3 It is not clear, however,
whether this unfavorable prognosis results from a greater
tumor mass at diagnosis, the proximity of tumors to inter-
nal organs, frequent incomplete resection, or the different
biology of these tumors. Similarly, increased NPY levels
Figure 4. Systemic neuropeptide Y (NPY) expression is ele-
vated in bone Ewing sarcoma (ES) compared with soft tissue
ES. (A) Serum NPY concentrations were compared between
patients with ES who had bone (B) or extraosseous (EO) pri-
mary tumors. These comparisons were made in the overall
patient population and within subgroups that had particular
tumor localization. (B) Messenger RNA (mRNA) levels of NPY
and its receptors (NPY receptor type 1, 2 and 5 [Y1R, Y2R,
Y5R]), and dipeptidyl peptidase IV (DPPIV) were measured
by using gene expression microarrays in tissues from 56
human ES primary tumors originating from bone (n 5 32) or
soft tissues (n 5 23) and were compared between the 2
groups.
Figure 5. In patients with localized Ewing sarcoma (ES), se-
rum neuropeptide Y (NPY) levels do not affect survival. (A)
ES patients with localized disease were divided into 4 groups
based on serum NPY levels (>75th percentile, 50th-75th per-
centile, 25th-50th percentile, and <25th percentile). Patients’
event-free survival (EFS) was compared between these
groups using the log-rank test, and no significant differences
between groups were detected. (B) The same approach
revealed no significant differences in overall survival between
patients with ES who had various NPY levels.
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in these tumors may result from their greater size or more
aggressive phenotype. The trend toward increased NPY
serum concentrations in patients with metastatic ES sug-
gest its elevated release associated with blood-borne
disease dissemination. This notion is further supported by
our previous experimental data indicating that a hypoxic
microenvironment, which is known to increase ES malig-
nancy, stimulates endogenous NPY and promotes its
Y2R/Y5R-mediated growth-promoting and prometastatic
actions.13
Analyses performed within a population of patients
who had localized disease indicated no effect of serum
NPY levels on the survival of patients with ES. However,
given a trend toward increased peptide levels in patients
with metastatic ES, the potential role of NPY as a prog-
nostic factor in the overall ES population cannot be
excluded. Nevertheless, even if further studies demon-
strate no prognostic value for NPY, systemic levels of the
peptide can be used to monitor disease progression and
response to treatment in the subset of patients with ele-
vated NPY release. This was proposed previously for
patients with neuroblastoma and pheochromocy-
toma.23,24 Moreover, high systemic levels of NPY may
identify a subset of potential candidates for anti-NPY
therapies among a population of patients with ES once
the role of the endogenous peptide in these tumors is fully
elucidated. Finally, the universal, fusion type-
independent tissue expression of NPY may serve as a
marker in differential diagnosis between ES and other
small blue round cell tumors.
NPY actions are modified by DPPIV, which cleaves
NPY and facilitates its Y2R/Y5R-mediated growth-
promoting and prometastatic effects.12,13 Because our
previous studies indicated elevated DPP activity in plasma
from mice bearing DPPIV-rich ES xenografts, we sought
to determine whether the same measure would apply to
patients with ES.12 The assay used in our study measured
the overall DPP activity in patients’ sera and did not dis-
tinguish between different types of DPPs. However,
DPPIV is the only known membrane DPP that can be
converted to a soluble enzyme by its shedding from the
cell surface, whereas other DPPs (DPP8 and DPP9) are
intracellular proteases.12 Therefore, DPP activity detecta-
ble in sera can be attributed mainly to DPPIV. Neverthe-
less, serum DPP activity in patients with ES did not differ
significantly from that observed in healthy controls and
patients with osteosarcoma. These data suggest that
enzyme shedding from ES tumors is not sufficient to
affect its activity in blood. Instead, the DPP activity de-
tectable in serum depends on nontumor sources, such as
endothelium and immune cells.13,18,19 This discrepancy
between animal studies and clinical data may be associated
with the relatively greater tumor burden in mice than in
patients.
Figure 6. Dipeptidyl peptidase (DPP) activity is not elevated
in sera from patients with Ewing sarcoma (ES), but its high
levels are associated with better event-free survival (EFS). (A)
DPP activity was measured in sera from healthy children (ages
6-18 years), patients with ES, and patients with osteosarcoma
using a colorimetric method. No significant differences were
observed between the experimental groups. (B) Patients with
ES who had localized disease were categorized into quartiles
based on their serum DPP activity. High DPP activity was
associated with significantly better EFS among patients with
ES, as determined by the log-rank test (P 5 .0067). (C) The
effect of DPP levels on the overall survival of patients with ES
who had localized disease, determined as described above,
did not achieve statistical significance (P 5 .1154).
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Despite the nontumor origin of DPPIV detected in
serum, its high activity was associated with significantly
better EFS in patients with ES and trended toward such
an effect on overall survival. This surprising discovery
may be associated with the known role of DPPIV in regu-
lating the immune response. DPPIV is a crucial factor in
activation and propagation of T lymphocytes and natural
killers, 2 key elements of the cellular immunity responsi-
ble for a host’s antitumor response.18,19 Thus, improved
overall survival of patients with high DPPIV activity may
reflect a more efficient immune response that inhibits dis-
ease progression. This observation strongly suggests that,
in the event that prometastatic actions of NPY are con-
firmed in animal models, directly blocking this pathway
will be a better therapeutic strategy than the previously
proposed inhibition of multifaceted DPPIV activity.12 It
also raises a question regarding the safety of long-term
administration of DPPIV inhibitors recently introduced
as routine treatment for diabetes.19
In summary, here, we provide the first evidence for
elevated systemic levels of NPY in patients with ES com-
parable to the levels described in patients with tumors of
sympathetic origin.14-17 Although we did not observe a
direct effect of high NPY levels on the survival of patients
with localized ES, the trend toward elevated NPY release
in patients with unfavorable disease features suggests a
potential role for the peptide in ES dissemination and
warrants further survival analyses that include patients at
the metastatic stage. This notion is also supported by our
previous data indicating that a hypoxic tumor microenvir-
onment activates the prometastatic actions of NPY in
ES.13 Moreover, increased systemic NPY levels and intra-
tumor expression of the entire NPY system in bone
tumors suggest a potential role of this pathway in ES bone
invasion. Conversely, the association of high DPP activity
with better survival implicates a potential role for DPPIV
in anticancer immune response.
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